- Home
- RPRX vs AFRM Comparison
RPRX vs AFRM Comparison
Compare RPRX & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- AFRM
- Stock Information
- Founded
- RPRX 1996
- AFRM 2012
- Country
- RPRX United States
- AFRM United States
- Employees
- RPRX N/A
- AFRM N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- AFRM Business Services
- Sector
- RPRX Health Care
- AFRM Consumer Discretionary
- Exchange
- RPRX Nasdaq
- AFRM Nasdaq
- Market Cap
- RPRX 14.2B
- AFRM 16.0B
- IPO Year
- RPRX 2020
- AFRM 2021
- Fundamental
- Price
- RPRX $31.03
- AFRM $34.20
- Analyst Decision
- RPRX Strong Buy
- AFRM Buy
- Analyst Count
- RPRX 5
- AFRM 21
- Target Price
- RPRX $41.60
- AFRM $68.44
- AVG Volume (30 Days)
- RPRX 4.7M
- AFRM 8.8M
- Earning Date
- RPRX 05-08-2025
- AFRM 05-07-2025
- Dividend Yield
- RPRX 2.77%
- AFRM N/A
- EPS Growth
- RPRX N/A
- AFRM N/A
- EPS
- RPRX 1.91
- AFRM N/A
- Revenue
- RPRX $2,263,576,000.00
- AFRM $2,800,203,000.00
- Revenue This Year
- RPRX $34.04
- AFRM $39.13
- Revenue Next Year
- RPRX $6.10
- AFRM $24.20
- P/E Ratio
- RPRX $16.63
- AFRM N/A
- Revenue Growth
- RPRX N/A
- AFRM 46.27
- 52 Week Low
- RPRX $24.05
- AFRM $22.25
- 52 Week High
- RPRX $34.20
- AFRM $82.53
- Technical
- Relative Strength Index (RSI)
- RPRX 36.17
- AFRM 28.03
- Support Level
- RPRX $30.82
- AFRM $42.40
- Resistance Level
- RPRX $31.85
- AFRM $48.75
- Average True Range (ATR)
- RPRX 0.76
- AFRM 3.22
- MACD
- RPRX -0.25
- AFRM -0.63
- Stochastic Oscillator
- RPRX 9.57
- AFRM 1.05
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About AFRM Affirm Holdings Inc.
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.